8 SEP 2023 Pharmaceuticals 1xbet 리뷰 collaborates with ShapeTX1xbet 리뷰 develop novel AAV gene therapies for ocular diseases
16 JUN 2020 Pharmaceuticals Launch of a 1xbet 리뷰 Combination Ophthalmic Solution for the Treatment of Glaucoma and Ocular Hypertension, AILAMIDE®Combination Ophthalmic Suspension
9 DEC 2019 Pharmaceuticals Senju and Otsuka Launch a 1xbet 리뷰 Treatment for Glaucoma and Ocular Hypertension - AIBETA®Combination Ophthalmic Solution
11 JAN 2017 Pharmaceuticals Otsuka Launches a 1xbet 리뷰 Treatment for Glaucoma and Ocular Hypertension - Mikeluna®Combination Ophthalmic Solution in Japan
28 SEP 2016 Pharmaceuticals 1xbet 리뷰 Receives Approval in Japan for Mikeluna®Combination Ophthalmic Solution, a 1xbet 리뷰 Treatment for Glaucoma and Ocular Hypertension
14 SEP 2016 Pharmaceuticals Announcement of Co-promotion of 1xbet 리뷰 Glaucoma Treatment(PDF: 45.7 KB)
14 JUN 2016 Pharmaceuticals Announcement of Termination of Co-Development and Co-Commercialization Agreements with Acucela, Inc.
1 OCT 2015 Pharmaceuticals 1xbet 리뷰 Drug Application for Carteolol Hydrochloride/ Latanoprost, a Novel Combined Ophthalmic Solution, Submitted in Japan for the Treatment of Glaucoma and Ocular Hypertension
9 MAY 2013 Pharmaceuticals Acucela and 1xbet 리뷰 Announce Phase IIa Clinical Results of Emixustat Hydrochloride (ACU-4429) in Patients with Geographic Atrophy (GA) Associated with Dry Age-related Macular Degeneration (AMD) at ARVO 2013 Annual Meeting
19 JUL 2012 Pharmaceuticals Acucela and 1xbet 리뷰 Announce the Initiation of a Phase 3 Clinical Trial to Evaluate Rebamipide Ophthalmic Suspension in Patients with Dry Eye Syndrome
6 MAY 2011 Pharmaceuticals Phase III Study Results for Rebamipide Ophthalmic Suspension for Dry Eye Announced at ARVO 2011
9 NOV 2010 Pharmaceuticals 1xbet 리뷰 Files for Regulatory Approval in Japan for Mucosta®Ophthalmic Suspension for Dry Eye
27 SEP 2010 Pharmaceuticals Otsuka Pharmaceutical and Acucela Enter 1xbet 리뷰 Co-Development and Co-Promotion Agreement for OPA-6566 for Glaucoma
17 MAR 2010 Pharmaceuticals 1xbet 리뷰 and Acucela Receive FDA Fast Track Designation for ACU-4429 in Patients with Dry AMD Novel, Oral Therapy in Phase 2 Clinical Trial for Dry AMD, A Leading Cause of Blindness in People Over Age 50
4 SEP 2008 Pharmaceuticals Acucela and 1xbet 리뷰 Enter Co-Development Agreement for ACU-4429 in Dry Age Related Macular Degeneration
4 SEP 2008 Pharmaceuticals Acucela and 1xbet 리뷰 Enter Co-Development Agreement for Rebamipide Ophthalmic Suspension for Dry Eye